Boehringer Ingelheim, a leading pharmaceutical company, has unveiled the new DDP-4 inhibitor treatment for those with type 2 diabetes, which is the most common form of diabetes often leading to chronic complications like cardiovascular, kidney a
Germany-based Boehringer Ingelheim, a top research-driven pharmaceutical company, has recorded a sales growth of 14.3 per cent during the first half of the year in the Mena region.
Net global sales rose by 3.1 per cent, currency-a
Boehringer Ingelheim and Eli Lilly and Company today announced a global agreement to jointly develop and commercialise a portfolio of diabetes compounds currently in mid- and late-stage development.
Included are Boehringer Ingelheim’s two